Research and Clinical Trials

Brief Description  
The purpose of this study is to evaluate the efficacy of duloxetine 30/60 mg once daily (QD) compared with placebo on the reduction of average pain severity during a 13-week, double-blind treatment phase in adolescents (aged 13 to 17 years) with Juvenille Primary Fibromyalgia Syndrome.
Who may be Eligible  
Male or female aged 13 to 17 with a diagnosis of Juvenille Primary Fibromyalgia Syndrome.
Speciality/Disorder  
Fibromyalgia
IRB Number  
CHS1-11-074
Principal Investigator  
Tcheremissine, Oleg

For More Information, Contact  Dineen  , Gardner
Phone:  (704) 446-7511  Fax:  (704) 446-7505  
Email:  dineen.gardner@carolinashealthcare.org
Address:465 North Wendover Road Charlotte, NC 28211
Close